• 1. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 2. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 3. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 4. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 5. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Recent Advances in the Study of Ethyl 2-(piperazin-1-yl)propanoate (CAS: 824414-06-4) and Its Applications in Chemical Biology and Medicine

Ethyl 2-(piperazin-1-yl)propanoate (CAS: 824414-06-4) is a compound of significant interest in the field of chemical biology and medicinal chemistry due to its versatile pharmacological properties and potential therapeutic applications. Recent studies have focused on its synthesis, structural optimization, and biological evaluation, shedding light on its mechanism of action and potential as a drug candidate. This research brief aims to summarize the latest findings related to this compound, providing insights into its current and future applications.

One of the key areas of research involving Ethyl 2-(piperazin-1-yl)propanoate is its role as a building block in the synthesis of more complex molecules. Recent publications have highlighted its utility in the development of novel piperazine derivatives, which are known for their broad-spectrum biological activities. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficient synthesis of Ethyl 2-(piperazin-1-yl)propanoate and its subsequent conversion into a series of analogs with enhanced binding affinity for serotonin receptors. These findings underscore the compound's potential in the design of central nervous system (CNS) therapeutics.

In addition to its synthetic applications, Ethyl 2-(piperazin-1-yl)propanoate has been investigated for its direct pharmacological effects. A recent preclinical study explored its anti-inflammatory and analgesic properties, revealing that the compound exhibits significant activity in animal models of chronic pain. The study, conducted by researchers at a leading pharmaceutical institute, identified the compound's ability to modulate key inflammatory pathways, suggesting its potential as a non-opioid analgesic. These results were published in the European Journal of Pharmacology in early 2024, marking a notable advancement in pain management research.

Another emerging area of interest is the compound's application in targeted drug delivery systems. A 2023 paper in Advanced Drug Delivery Reviews discussed the use of Ethyl 2-(piperazin-1-yl)propanoate as a linker in prodrug formulations. The study demonstrated that the compound's chemical stability and biocompatibility make it an excellent candidate for conjugating therapeutic agents to targeting moieties, thereby improving drug efficacy and reducing off-target effects. This innovation has significant implications for the treatment of cancers and other diseases requiring precise drug delivery.

Despite these promising developments, challenges remain in the clinical translation of Ethyl 2-(piperazin-1-yl)propanoate-based therapies. Issues such as bioavailability, metabolic stability, and potential toxicity need to be addressed through further research. Ongoing studies are focusing on structural modifications to enhance the compound's pharmacokinetic profile while retaining its therapeutic benefits. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate progress in this area.

In conclusion, Ethyl 2-(piperazin-1-yl)propanoate (CAS: 824414-06-4) continues to be a molecule of great interest in chemical biology and medicinal research. Its versatility as a synthetic intermediate, combined with its direct pharmacological effects, positions it as a valuable tool for drug discovery and development. Future research will likely explore its applications in additional therapeutic areas, further solidifying its role in advancing modern medicine.

• 223128-18-5(ethyl 2-(ethylamino)propanoate)
• 734521-58-5(2-Propanaminium,N-ethyl-1-methoxy-N,N-dimethyl-1-oxo-(9CI))
• 201803-58-9(methyl 2-(piperazin-1-yl)propanoate)
• 476493-07-9(ethyl 1-methylpiperazine-2-carboxylate)
• 917952-93-3(Alanine, N-(2-ethoxy-1-methyl-2-oxoethyl)-, ethyl ester (9CI))
• 63285-60-9(Ethyl 4-Methylpiperazine-2-carboxylate)
• 32418-62-5(Ethyl 2-morpholin-4-ylpropanoate)
• 90729-01-4(Ethyl 1,4-dimethylpiperazine-2-carboxylate)
• 28920-63-0(Propanedioic acid,2-(4-methyl-1-piperazinyl)-, 1,3-diethyl ester)
• 149912-14-1(L-Alanine, N-ethyl-,ethyl ester)